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JOURNAL OF HEPATOLOGYControversy on the role of FoxP3+ regulatory T cells in ﬁbrogenesis in
chronic hepatitis C virus infectionsTo the Editor:
We read with interest the manuscript by Langhans and
colleagues. The authors identiﬁed a subset of intrahepatic FoxP3+
regulatory T cells (Treg) that produce IL-8 in chronic hepatitis C
virus (HCV) infected patients, and the authors suggested that
these cells promote liver ﬁbrosis through stimulation of hepatic
stellate cells [1]. This article is very timely and highly relevant
in an age where novel therapeutic strategies based on the use
of direct-acting antivirals are expected to lead to viral eradication
in most chronic HCV patients who undergo treatment. However,
despite dramatically improved viral eradication rates, the detri-
mental consequences of liver pathology and ﬁbrosis, such as
decompensated liver cirrhosis and hepatocellular carcinoma,
remain an issue, and detailed understanding of ﬁbrosis is needed.
The paper by Langhans et al.makes an important contribution
to better understand the role of Treg in ﬁbrosis in chronic HCV by
showing that IL-8-secreting Treg are enriched in the liver and are
detected especially at the transition areas of ﬁbrosis. Although
this is a very intriguing observation that identiﬁes a functionally
specialized fraction within the Treg pool of cells, it also raises a
number of questions. First of all, only a minority of liver FoxP3+
Treg produce IL-8 (on average 4.5%), while it is known that
Kupffer cells, but also hepatocytes, endothelial cells, epithelial
cells and ﬁbroblasts are major sources of IL-8. The paper does
not clarify what determines that Treg-derived IL-8 promotes
ﬁbrinogenesis, whereas the importance of IL-8 derived from
other liver cells is still unknown. Importantly, the IL-8 levels
secreted by these cells are likely magnitudes higher. Next, an
interesting ﬁnding from the microarray analysis presented by
the authors is that Treg clones generated from cells from chronic
HCV patients also express IFN-c, besides IL-8. Both cytokines are
expressed at lower levels by clones from patients with spontane-
ously resolved HCV infections. It would be relevant to examine
whether the IL-8/IFN-c producing Treg clones also possess effec-
tor activities that are independent of IL-8 and may promote ﬁbro-
sis. In this respect it is important to mention that a general
feature of tissue-residing T cells is an activated phenotype [2],
which may be more pronounced in livers from persistent vs.
resolved patients. Finally, IFN-c producing capacity is generally
not a feature of FoxP3+ Treg, which raises the question whether
the Treg clones described by Langhans et al., are representative
for intrahepatic FoxP3+ Treg in vivo.
In apparent contradiction with the population of IL-8 secret-
ing Treg described by Langhans et al., we recently published data
in the Journal of Hepatology in line with the widely accepted par-
adigm that FoxP3+ Treg limit immunopathology at the cost of
insufﬁcient protective pathogen-speciﬁc immune responses
[3,4]. Our ﬁndings showed that FoxP3+ Treg were abundantly
present in chronic HCV infected livers, but not in healthy livers,
and primarily resided within the portal tracts in close proximity
to the lymphocytic inﬁltrate, which is in line with previous
ﬁndings published in the Journal of Hepatology by two indepen-
dent groups [5,6]. Additionally, in our hands, higher frequencies
of FoxP3+ Treg were present in livers of chronic HCV patients
without or with mild ﬁbrosis [4]. Although Langhans and
colleagues kindly referred to our publication, they omitted to
discuss these key ﬁndings.
If it holds true that IL-8 production by FoxP3+ Treg substan-
tially contributes to liver ﬁbrosis, we propose that, analogous to
TGF-b [7–9], FoxP3+ Treg play a dual role both promoting and
limiting ﬁbrosis. While FoxP3+ Treg generally seem to protect
against liver ﬁbrosis [4], the small subset of IL-8-expressing
FoxP3+ Treg may deteriorate liver pathology [1]. Importantly, in
contrast to what is often postulated, we recently showed that
FoxP3+ Treg are retained in the liver long after HCV eradication,
even after HCV RNA was undetectable in serum for more than
12 months, suggesting ongoing immunopathology and regulation
by intrahepatic FoxP3+ Treg [10]. These FoxP3+ Treg differed
phenotypically from their counterparts present during ongoing
persistent infection. We strongly feel that these Treg are unlikely
to further promote ﬁbrosis in the absence of HCV, but rather act
as memory Treg. The question remains whether IL-8 production
by FoxP3+ Treg is maintained after viral eradication, or whether
IL-8 expression is reduced. Our data as well as Langhans’ ﬁndings
demonstrate convincingly that the Treg compartment in HCV
infected livers is heterogeneous, and more detailed analysis, both
phenotypically as well as functionally is urgently needed to elu-
cidate the importance of FoxP3+ Treg in disease progression in
the inﬂamed liver.
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Reply to: ‘‘Controversy on the role of FoxP3+ regulatory T cells
in ﬁbrogenesis in chronic hepatitis C virus infections’’
Diversity of Foxp3+CD4+ T cells and regulation of ﬁbrosis in
hepatitis C – At the tip of the iceberg?
To the Editor:
We are grateful that Claassen et al. draw attention to several
issues in our manuscript on ‘‘Intrahepatic IL-8 producing
Foxp3+CD4+ regulatory T cells and ﬁbrogenesis in chronic
hepatitis C’’ [1] which had not been discussed in depth and thus
might lead to misleading conclusions.
We agree, that IL-8+Foxp3+CD4+ T cells comprise only a small
population of intrahepatic immune cells and that other types of
intrahepatic cells also produce IL-8. However, in line with the
report by Zimmermann et al. [2], macrophages were the only
other cells in hepatitis C, which in addition to CD4+ T cells pro-
duced sufﬁcient IL-8 as to enable in situ detection by immunoﬂu-
orescence. Unlike IL-8+CD4+ T cells, which were located
preferentially at the boundaries of ﬁbrotic areas, macrophages
formed cell clusters at regions of necrosis and inﬂammation
(see Fig. 1). Furthermore, IL-8+CD4+ T cells can be triggered by
HCV antigens [3] and thus are probably activated continuously
by antigen in chronic hepatitis C. Taken together these ﬁndings
suggest a regulatory role of IL-8+CD4+ T cells in HCV-infected liv-
ers. In support of this hypothesis we directly demonstrated
induction of ﬁbrogenesis in primary human hepatic stellate cells
by in vitro co-culture experiments. As reported previously the
same type of IL-8 producing CD4+ regulatory T cells also exerts
other functions, e.g., our regulatory T cell clones inhibit activity
of CD4+ effector T cells by releasing the cytokines IL-10 and IL-
35 [3].
Concerning interferon-c the comment of Claassen et al.
illustrates that data frommicroarray analysis must be interpreted
with caution. As can be seen in the supplementary ﬁle to our
previously published data [3], the regulatory T cell clones studied
by microarray analysis (T1_7, H7_3, H7_16) only produced
negligible amounts of interferon-c even upon stimulation with
mitogen (<5 pg/ml), whereas bona ﬁde TH1 cells produced
800–6000 pg/ml under the same conditions. Of note, the regula-
tory T cell clones even suppressed interferon-c production of TH1
reporter cells in co-culture experiments (see Fig. 2). This consti-
tutes further experimental evidence suggesting a dual role of
Foxp3+CD4+ regulatory T cells in both regulation of ﬁbrosis and
inhibition of inﬂammatory activity. To guard against false inter-
pretation of our microarray data, we have conﬁrmed at the
protein level that regulatory T cell clones as well as freshly iso-
lated Foxp3+CD4+ T cells produce IL-8 in chronic hepatitis C.
These ﬁndings indicate that IL-8 production of regulatory T cells
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